论文信息 - COVID-19 Outcomes in Solid Organ Transplant Recipients Who Received Tixagevimab-cilgavimab Prophylaxis and/or Bebtelovimab Treatment in a Nurse-driven Monoclonal Antibody Program During the Omicron Surge - 字舞流文

COVID-19 Outcomes in Solid Organ Transplant Recipients Who Received Tixagevimab-cilgavimab Prophylaxis and/or Bebtelovimab Treatment in a Nurse-driven Monoclonal Antibody Program During the Omicron Surge

P. Shah | D. Segev | R. Avery | Sonsoles Salto-Alejandre | W. Werbel | W. Cochran | Lindsay Barker | D. Brennan | Heba Mostafa | Jaclyn Bannon | Julie Langlee | Kristina Freed | D. Carter | Dillon Goddard

[1] D. Salerno,et al. Bebtelovimab for Treatment of COVID-19 in Ambulatory Solid Organ Transplant Recipients , 2022, Transplantation.

[2] R. Razonable,et al. Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild‐to‐moderate coronavirus disease 2019 during the Omicron epoch , 2022, Transplant infectious disease : an official journal of the Transplantation Society.

[3] P. Shah,et al. Short-term Outcomes in a Nurse Coordinator-led and Nurse Practitioner-led Sotrovimab Initiative for Solid Organ Transplant Recipients During the Omicron Surge. , 2022, Transplantation.